Drug survival, effectiveness and safety of ixekizumab for moderate‐to‐severe psoriasis up to 5 years.

MLA

Mastorino, L., et al. “Drug Survival, Effectiveness and Safety of Ixekizumab for Moderate‐to‐severe Psoriasis up to 5 Years.” Journal of the European Academy of Dermatology & Venereology, vol. 38, no. 3, Mar. 2024, pp. 568–75. EBSCOhost, https://doi.org/10.1111/jdv.19682.

APA

Mastorino, L., Dapavo, P., Burzi, L., Rosset, F., Giunipero, di C. I., Leo, F., Verrone, A., Stroppiana, E., Ortoncelli, M., Ribero, S., & Quaglino, P. (2024). Drug survival, effectiveness and safety of ixekizumab for moderate‐to‐severe psoriasis up to 5 years. Journal of the European Academy of Dermatology & Venereology, 38(3), 568–575. https://doi.org/10.1111/jdv.19682

Chicago

Mastorino, L., P. Dapavo, L. Burzi, F. Rosset, di Corteranzo, I. Giunipero, F. Leo, A. Verrone, et al. 2024. “Drug Survival, Effectiveness and Safety of Ixekizumab for Moderate‐to‐severe Psoriasis up to 5 Years.” Journal of the European Academy of Dermatology & Venereology 38 (3): 568–75. doi:10.1111/jdv.19682.